Equival Biocenter

Our Bioequivalence Center is a leader in the field of pharmaceutical research and regulation in Algeria. We specialize in conducting bioequivalence studies, which play a crucial role in the development and approval of generic medications. Our primary missions involve evaluating the bioequivalence between generic products and reference drugs. Through our stringent protocols and advanced analytical methods, we provide reliable and precise data to support the regulatory registration of medications. As a Bioequivalence Center, we play a vital role in the drug development process by assisting pharmaceutical companies in demonstrating the effectiveness and safety of their products. Our studies contribute to the evaluation of the quality, efficacy, and safety of generic medications, expanding access to essential treatments while reducing costs for patients. Our highly qualified experts work closely with regulatory authorities to ensure compliance with national and international bioequivalence requirements. We take pride in our commitment to scientific excellence, integrity, and transparency in all our activities. In summary, our Bioequivalence Center is dedicated to conducting high-quality bioequivalence studies to support the development and approval of generic medications. We provide precise and reliable data to help pharmaceutical companies achieve their regulatory objectives and improve the health and well-being of patients. We offer our services to pharmaceutical companies in Algeria and worldwide.